The selective BCL-2 inhibitor venetoclax showed therapeutic effect in a few cases of relapsed/refractory AL amyloidosis (Leung et al., 2018; Ghilardi et al., 2019; Premkumar et al., 2019), in line with positive findings against relapsed/refractory t(11;14)-positive multiple myeloma cases, both as a single agent or in combination with bortezomib (Kumar et al., 2017; Moreau et al., 2017). Here, BCL2 is linked to AL amyloidosis.